Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer

被引:9
|
作者
Pliakou, Evangelia [1 ]
Lampropoulou, Dimitra Ioanna [2 ]
Dovrolis, Nikolas [3 ]
Chrysikos, Dimosthenis [4 ]
Filippou, Dimitrios [5 ]
Papadimitriou, Christos [6 ]
Vezakis, Antonios [7 ]
Aravantinos, Gerasimos [1 ]
Gazouli, Maria [8 ]
机构
[1] Gen Oncol Hosp Kifissia Agioi Anargiroi, Dept Med Oncol 2, Nea Kifissia, Athens 14564, Greece
[2] ECONCARE, Athens 11528, Greece
[3] Democritus Univ Thrace, Dept Med, Lab Biol, Alexandroupolis 68100, Greece
[4] Natl & Kapodistrian Univ Athens, Hippoctat Hosp, Med Sch, Dept Propaedeut Surg 1, Athens 11528, Greece
[5] Natl & Kapodistrian Univ Athens, Med Sch, Dept Anat, Athens 11527, Greece
[6] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Med Sch, Dept Surg 2, Athens 11528, Greece
[7] Natl & Kapodistrian Univ Athens, Aretaie Univ Hosp, Med Sch, Dept Surg, Athens 11528, Greece
[8] Natl & Kapodistrian Univ Athens, Med Sch, Dept Basic Med Sci, Lab Biol, Athens 11527, Greece
关键词
microRNAs; colorectal cancer; machine learning; artificial intelligence; irinotecan; resistance; DOWN-REGULATION; GASTRIC-CANCER; CELLS; ANGIOGENESIS; BEVACIZUMAB; MANAGEMENT; ONCOLOGY; SURVIVAL; GROWTH;
D O I
10.3390/ijms24010046
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer represents a leading cause of cancer-related morbidity and mortality. Despite improvements, chemotherapy remains the backbone of colorectal cancer treatment. The aim of this study is to investigate the variation of circulating microRNA expression profiles and the response to irinotecan-based treatment in metastatic colorectal cancer and to identify relevant target genes and molecular functions. Serum samples from 95 metastatic colorectal cancer patients were analyzed. The microRNA expression was tested with a NucleoSpin miRNA kit (Machnery-Nagel, Germany), and a machine learning approach was subsequently applied for microRNA profiling. The top 10 upregulated microRNAs in the non-responders group were hsa-miR-181b-5p, hsa-miR-10b-5p, hsa-let-7f-5p, hsa-miR-181a-5p, hsa-miR-181d-5p, hsa-miR-301a-3p, hsa-miR-92a-3p, hsa-miR-155-5p, hsa-miR-30c-5p, and hsa-let-7i-5p. Similarly, the top 10 downregulated microRNAs were hsa-let-7d-5p, hsa-let-7c-5p, hsa-miR-215-5p, hsa-miR-143-3p, hsa-let-7a-5p, hsa-miR-10a-5p, hsa-miR-142-5p, hsa-miR-148a-3p, hsa-miR-122-5p, and hsa-miR-17-5p. The upregulation of microRNAs in the miR-181 family and the downregulation of those in the let-7 family appear to be mostly involved with non-responsiveness to irinotecan-based treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer
    Horisberger, Karoline
    Erben, Philipp
    Muessle, Benjamin
    Woernle, Christoph
    Stroebel, Philipp
    Kaehler, Georg
    Wenz, Frederik
    Hochhaus, Andreas
    Post, Stefan
    Willeke, Frank
    Hofheinz, Ralf-Dieter
    ANTI-CANCER DRUGS, 2009, 20 (06) : 519 - 524
  • [22] Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Uner, Aytug
    Yamac, Deniz
    Coskun, Ugur
    Kaya, Ali Osman
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    CANCER INVESTIGATION, 2010, 28 (01) : 33 - 37
  • [23] MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer
    Dimitra-Ioanna Lampropoulou
    Gerasimos Aravantinos
    Konstantinos Laschos
    Theodosis Theodosopoulos
    Christos Papadimitriou
    Maria Gazouli
    International Journal of Colorectal Disease, 2019, 34 : 1871 - 1877
  • [24] Pharmacogenetic Tailoring of Irinotecan-based First-line Chemotherapy in Metastatic Colorectal Cancer: Results of a Pilot Study
    Freyer, Gilles
    Duret, Aude
    Milano, Gerard
    Chatelut, Etienne
    Rebischung, Christine
    Delord, Jean-Pierre
    Merrouche, Yacine
    Lledo, Gerard
    Etienne, Marie-Christine
    Falandry, Claire
    ANTICANCER RESEARCH, 2011, 31 (01) : 359 - 366
  • [25] KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin- or irinotecan-based treatment
    Soeda, Hiroshi
    Shimodaira, Hideki
    Waianabe, Mika
    Suzuki, Takao
    Gamo, Makio
    Takahashi, Masanobu
    Komine, Keigo
    Kato, Shunsuke
    Ishioka, Chikashi
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 356 - 362
  • [26] Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
    Li, Minmin
    Wang, Zhehai
    Guo, Jun
    Liu, Jie
    Li, Changzheng
    Liu, Lin
    Shi, Huan
    Liu, Liyan
    Li, Huihui
    Xie, Chao
    Zhang, Xia
    Sun, Wenwen
    Fang, Shu
    Bi, Xiang
    ONCOTARGETS AND THERAPY, 2014, 7 : 1653 - 1661
  • [27] Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
    Imai, Hiroo
    Saijo, Ken
    Komine, Keigo
    Yoshida, Yuya
    Sasaki, Keiju
    Suzuki, Asako
    Ouchi, Kota
    Takahashi, Masahiro
    Takahashi, Shin
    Shirota, Hidekazu
    Takahashi, Masanobu
    Ishioka, Chikashi
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [28] Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer
    Giessen, Clemens
    Stintzing, Sebastian
    Laubender, Ruediger Paul
    Ankerst, Donna Pauler
    Schulz, Christoph
    Moosmann, Nicolas
    Modest, Dominik Paul
    Schalhorn, Andreas
    von Weikersthal, Ludwig Fischer
    Heinemann, Volker
    CLINICAL COLORECTAL CANCER, 2011, 10 (04) : 317 - 324
  • [29] UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    Christoph Schulz
    Volker Heinemann
    Andreas Schalhorn
    Nikolas Moosmann
    Thomas Zwingers
    Stefan Boeck
    Clemens Giessen
    Hans-Joachim Stemmler
    World Journal of Gastroenterology, 2009, 15 (40) : 5058 - 5066
  • [30] UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    Schulz, Christoph
    Heinemann, Volker
    Schalhorn, Andreas
    Moosmann, Nikolas
    Zwingers, Thomas
    Boeck, Stefan
    Giessen, Clemens
    Stemmler, Hans-Joachim
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (40) : 5058 - 5066